Zhou Quan, Li Hao, Jing Jingjing, Yuan Yuan, Sun Liping
Tumor Etiology and Screening Department of Cancer Institute, The First Hospital of China Medical University, Shenyang 110001, People's Republic of China.
Key Laboratory of Cancer Etiology and Prevention, The First Hospital of China Medical University, Liaoning Provincial Education Department, Shenyang 110001, People's Republic of China.
Onco Targets Ther. 2020 Apr 2;13:2795-2805. doi: 10.2147/OTT.S239965. eCollection 2020.
Long non-coding RNAs (lncRNAs) participate in a series of pathological processes in tumorigenesis. Reports show that C5orf66-AS1, an antisense lncRNA, is expressed in various tumors. However, the role of C5orf66-AS1 in gastric cancer (GC) has not been fully clarified. The study focused on the expression patterns and serum level of C5orf66-AS1 in GC to explore its potential application in GC screening and diagnosis. The effects of C5orf66-AS1 on GC cells were also analyzed.
Tissue and serum samples were used for RNA isolation. Expression levels of C5orf66-AS1 in GC tissues, serum, and cell lines were detected using quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR). CCK-8, transwell, and wound healing assays were performed to determine the effects of C5orf66-AS1 on GC cell behavior.
C5orf66-AS1 expression was downregulated in GC cells compared to that in adjacent normal tissues. Serum C5orf66-AS1 levels were significantly lower in GC patients than in superficial gastritis (GS) and atrophic gastritis (GA) patients. Low serum expression of C5orf66-AS1 was associated with an increased risk of gastric dysplasia (GD) and GC. Receiver operating characteristic curve results showed that the area under curve (AUC) for GC was 0.688, with a sensitivity and specificity of 77.5% and 53.6%, respectively. For the GD + early gastric cancer (ECG) group, the AUC was 0.789, with a sensitivity and specificity of 85.15% and 62.86%, respectively. Correlation analyses of clinicopathological parameters showed that serum C5orf66-AS1 was predominantly associated with Lauren type, TNM stages, pTNM stages, and vessel tumor emboli. Additionally, in vitro overexpression of C5orf66-AS1 in AGS cells inhibited cell proliferation, migration, and invasion.
Decreased expression levels of serum C5orf66-AS1 can be utilized for diagnosis of GC, especially for early diagnosis. The low level of serum C5orf66-AS1 indicated poor biological behavior of tumors in GC patients. In addition, C5orf66-AS1 can inhibit GC cell proliferation, migration, and invasion.
长链非编码RNA（lncRNAs）参与肿瘤发生过程中的一系列病理过程。报告显示，反义lncRNA C5orf66-AS1在多种肿瘤中表达。然而，C5orf66-AS1在胃癌（GC）中的作用尚未完全阐明。本研究聚焦于C5orf66-AS1在GC中的表达模式和血清水平，以探索其在GC筛查和诊断中的潜在应用。同时也分析了C5orf66-AS1对GC细胞的影响。
使用组织和血清样本进行RNA分离。采用定量实时逆转录聚合酶链反应（qRT-PCR）检测GC组织、血清和细胞系中C5orf66-AS1的表达水平。进行CCK-8、Transwell和伤口愈合试验，以确定C5orf66-AS1对GC细胞行为的影响。
与相邻正常组织相比，GC细胞中C5orf66-AS1表达下调。GC患者血清C5orf66-AS1水平显著低于浅表性胃炎（GS）和萎缩性胃炎（GA）患者。血清C5orf66-AS1低表达与胃发育异常（GD）和GC风险增加相关。受试者工作特征曲线结果显示，GC的曲线下面积（AUC）为(0.688)，敏感性和特异性分别为(77.5%)和(53.6%)。对于GD +早期胃癌（ECG）组，AUC为(0.789)，敏感性和特异性分别为(85.15%)和(62.86%)。临床病理参数的相关性分析表明，血清C5orf66-AS1主要与Lauren分型、TNM分期、pTNM分期和血管肿瘤栓子相关。此外，在AGS细胞中体外过表达C5orf66-AS1可抑制细胞增殖、迁移和侵袭。
血清C5orf66-AS1表达水平降低可用于GC的诊断，尤其是早期诊断。血清C5orf66-AS1水平低表明GC患者肿瘤的生物学行为较差。此外，C5orf66-AS1可抑制GC细胞的增殖、迁移和侵袭。
